AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2025
Jan 8, 2025
32254_dirs_2025-01-08_fb6f7ed1-93f5-4fa0-a195-509cea78f40a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2025-01-08
Reporting Person: Sanders Reginald J. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-08 | Stock Options (Right to buy) | $9.11 | A | 80000.00 | Acquired | 2035-01-08 | Common Stock (80000.00) | Direct |
Footnotes
F1: The option becomes exercisable in three ratable annual installments beginning on January 8, 2026.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7